Compare RLMD & RFMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | RFMZ |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.7M | 309.3M |
| IPO Year | 2012 | 2020 |
| Metric | RLMD | RFMZ |
|---|---|---|
| Price | $4.48 | $12.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.25 | N/A |
| AVG Volume (30 Days) | ★ 545.8K | 84.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.24 | $11.76 |
| 52 Week High | $5.12 | $13.96 |
| Indicator | RLMD | RFMZ |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 35.45 |
| Support Level | $3.49 | $12.78 |
| Resistance Level | $4.56 | $13.17 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 70.89 | 5.09 |
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.